| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/13/2011 | US20110008325 Inhalant Formulation Containing Sulfoalkyl Ether Cyclodextrin and Corticosteroid Prepared from a Unit Dose Suspension |
| 01/13/2011 | US20110008324 Antibody Selective for a Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor and Uses Thereof |
| 01/13/2011 | US20110008320 Further Use of Protein Kinase N Beta |
| 01/13/2011 | US20110008311 Animal Model and Use of 17Beta-Hydroxysteroid Dehydrogenase Type 7 in the Diagnosis of Anencephaly |
| 01/13/2011 | US20110008307 Cephalotaxine Alkaloid Compositions and Uses Thereof |
| 01/13/2011 | US20110008306 Creatine-ligand compounds and methods of use thereof |
| 01/13/2011 | US20110008305 Nano-emulsion composition of coenzyme q10 |
| 01/13/2011 | US20110008304 Use of cells to facilitate targeted delivery of nanoparticle therapies |
| 01/13/2011 | US20110008302 Compositions and methods for immortalizing cells and screening for anti-cancer agents |
| 01/13/2011 | US20110008297 Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling |
| 01/13/2011 | US20110008293 Device and method for preparing microparticles |
| 01/13/2011 | US20110008291 Use of antifungal compositions to treat upper gastrointestinal conditions |
| 01/13/2011 | US20110008288 Hepatitis c virus inhibitors |
| 01/13/2011 | US20110008287 Methods and means for the treatment of hpv induced intraepithelial neoplasias |
| 01/13/2011 | US20110008278 Modulators of paraptosis and related methods |
| 01/13/2011 | US20110008277 Polyol-based polymers |
| 01/13/2011 | US20110008276 Ethyleneoxide butyleneoxide block copolymer compositions |
| 01/13/2011 | US20110008272 Use of Creatine or Creatine Compounds for Skin Preservation |
| 01/13/2011 | US20110008271 Rosacea treatments using polymetal complexes |
| 01/13/2011 | US20110008269 Compositions and Methods Which Modulate G-Protein Signaling for the Treatment of Inflammatory Disorders such as Asthma and Allergic Conjunctivitis |
| 01/13/2011 | US20110008268 Phenyl substituted pyrazinoylguanidine sodium channel blockers possessing beta agonist activity |
| 01/13/2011 | US20110008266 Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
| 01/13/2011 | US20110008262 Drug delivery system targeting to estrogen receptor over-expressed cells |
| 01/13/2011 | US20110008260 Use of Nanocrystals for Drug Delivery from a Balloon |
| 01/13/2011 | US20110008259 Modulators of cystic fibrosis transmembrane conductance regulator |
| 01/13/2011 | US20110008258 Methods relating to breathing disorders |
| 01/13/2011 | US20110008257 Inhibitors of bruton's tyrosine kinase |
| 01/13/2011 | US20110005960 Stable pharmaceutical compositions of carvedilol |
| 01/13/2011 | US20110005947 Inhibitors of jak |
| 01/13/2011 | US20110005518 Methods and unit dose formulations for the inhalation administration of aminoglycoside antibiotics |
| 01/13/2011 | DE102010026684A1 Hemmung des Überlebens von Knochenkrebs durch Cyclohexenonverbindungen aus Antrodia camphorata Inhibition of survival of bone cancer cyclohexenone from Antrodia camphorata by |
| 01/13/2011 | DE102009032902A1 Induktion von α-Helix-Konformationen in Proteinen und Peptiden Induction of α-helical conformations in proteins and peptides |
| 01/13/2011 | DE102009011153A1 Hormonal postcoital contraceptive, useful for preventing the occurrence of pregnancy, on the basis of a progestin, or estrogen and progestin, applied to women after unprotected heterosexual intercourse |
| 01/13/2011 | CA2769488A1 Topical antifungal composition |
| 01/13/2011 | CA2767811A1 Combination therapy for the treatment of diabetes |
| 01/13/2011 | CA2767808A1 Compositions and methods for inhibition of cancers |
| 01/13/2011 | CA2767785A1 Diyne compositions |
| 01/13/2011 | CA2767711A1 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis |
| 01/13/2011 | CA2767697A1 Hdac 6 inhibitor-based methods for treating cancer |
| 01/13/2011 | CA2767692A1 Pharmaceutical composition for a hepatitis c viral protease inhibitor |
| 01/13/2011 | CA2767664A1 Compounds and compositions for the treatment of parasitic diseases |
| 01/13/2011 | CA2767661A1 Method of wound healing and scar modulation |
| 01/13/2011 | CA2767648A1 Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
| 01/13/2011 | CA2767646A1 Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
| 01/13/2011 | CA2767592A1 Salts of rasagiline and pharmaceutical preparations thereof |
| 01/13/2011 | CA2767576A1 Pharmaceutical compositions |
| 01/13/2011 | CA2767561A1 Oncolytic viruses and methods for treating neoplastic disorders |
| 01/13/2011 | CA2767556A1 Azabicyclo compound and salt thereof |
| 01/13/2011 | CA2767489A1 A crystalline form of posaconazole |
| 01/13/2011 | CA2767476A1 Indazolyl-substituted dihydroisoxazolopyridines and methods of use thereof |
| 01/13/2011 | CA2767474A1 Substituted pyrrolidinone as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use |
| 01/13/2011 | CA2767467A1 1-(6 members azo-heterocyclic)-pyrrolin-2-one compounds as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use |
| 01/13/2011 | CA2767460A1 Liquid pharmaceutical form of alkylphosphocholine and method of preparing same |
| 01/13/2011 | CA2767459A1 Ethyleneoxide butyleneoxide block copolymer compositions |
| 01/13/2011 | CA2767440A1 Pharmaceutical compositions and solid forms |
| 01/13/2011 | CA2767339A1 Pharmaceutical compositions and therapeutic methods employing a combination of a manganese complex compound and a non-manganese complex form of the compound |
| 01/13/2011 | CA2767298A1 Cyclic triazo sodium channel blockers |
| 01/13/2011 | CA2767296A1 Cyclic triazo sodium channel blockers |
| 01/13/2011 | CA2767291A1 Compounds useful as medicaments |
| 01/13/2011 | CA2767288A1 Novel polymorphic form of teriflunomide salts |
| 01/13/2011 | CA2767257A1 Stable crystalline polymorphs of the dipotassium salt of (s)-2-{4-[2-(2,4-diamino-quinazolin-6-yl)-ethyl]-benzoylamino}-4-methylene-penta nedioic acid |
| 01/13/2011 | CA2767253A1 Novel nucleic acid prodrugs and methods of use thereof |
| 01/13/2011 | CA2767238A1 Formulations of 6- (5-chloro-2-pyridyl) - 5- [ (4-methyl-1-piperazinyl) carbonyloxy] - 7-0x0-6, 7- dihydro-5h-phyrrolo [3, 4-b] pyrazine |
| 01/13/2011 | CA2767143A1 Tablet having hollow structure |
| 01/13/2011 | CA2767112A1 Etomidate analogues that do not inhibit adrenocortical steroid synthesis |
| 01/13/2011 | CA2767079A1 Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
| 01/13/2011 | CA2767043A1 Inhibiting inflammation with milk oligosaccharides |
| 01/13/2011 | CA2767008A1 Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| 01/13/2011 | CA2766937A1 Combined preparation for use as a medicament |
| 01/13/2011 | CA2766643A1 Tofa analogs useful in treating dermatological disorders or conditions |
| 01/13/2011 | CA2766563A1 Sanitizing composition |
| 01/13/2011 | CA2766343A1 Platelet-activating factor receptor antagonists |
| 01/13/2011 | CA2765919A1 New antiviral compounds useful for the treatment or the prevention of epidemic keratoconjonctivitis |
| 01/13/2011 | CA2765529A1 Acid pump antagonist for treatment of diseases involved in abnormal gastrointestinal motility |
| 01/13/2011 | CA2765463A1 Methods for treating or preventing fatigue |
| 01/13/2011 | CA2765157A1 Method of treating age related disorders |
| 01/13/2011 | CA2765066A1 Compositions and methods for enhancing virus efficacy |
| 01/13/2011 | CA2764792A1 Composition comprising bioactive amino acids and/or peptides and marine oil in a stable oil-in-water emulsion, and the use of said composition as a functional or therapeutic composition |
| 01/13/2011 | CA2764740A1 Sodium ibuprofen tablets and methods of manufacturing pharmaceutical compositions including sodium ibuprofen |
| 01/13/2011 | CA2764126A1 Diphenyl sulfide derivatives and medicines containing same as active ingredient |
| 01/13/2011 | CA2762524A1 Carbon nanotubes complexed with multiple bioactive agents and methods related thereto |
| 01/13/2011 | CA2760176A1 Use of benzydamine in the treatment of p40-dependent diseases |
| 01/13/2011 | CA2748765A1 Compounds, compositions, and methods for preventing metastasis of cancer cells |
| 01/13/2011 | CA2697978A1 Lower dosage strength imiquimod formulations and short dosing regimens for treating genital warts |
| 01/12/2011 | EP2272985A1 Antisense modulation of apolipoprotein (A) expression |
| 01/12/2011 | EP2272970A1 High viscosity xanthan polymer preparations |
| 01/12/2011 | EP2272861A1 Polyepitope carrier protein |
| 01/12/2011 | EP2272859A2 Immunological herpes simplex virus antigens and methods for use thereof |
| 01/12/2011 | EP2272854A1 Novel glycolipid and use thereof |
| 01/12/2011 | EP2272848A1 Xanthine derivatives as selective HM74A agonists |
| 01/12/2011 | EP2272847A1 Enantiomers and their use as monoamine neurotransmitter re-uptake inhibitors |
| 01/12/2011 | EP2272845A2 Benzophenone thiazole derivatives useful for inhibiting formation of microtubule and method for producing the same |
| 01/12/2011 | EP2272844A1 Five-membered ring compound |
| 01/12/2011 | EP2272843A1 Quinoline compound |
| 01/12/2011 | EP2272841A1 Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
| 01/12/2011 | EP2272840A1 Intermediate compound for the preparation of halichondrin analogs |
| 01/12/2011 | EP2272839A1 Intermediate compounds for the preparation of halichondrin analogs |
| 01/12/2011 | EP2272838A1 Fostriecin derivatives and the pharmaceutical uses thereof |
| 01/12/2011 | EP2272835A1 Novel five-membered ring compound |
| 01/12/2011 | EP2272834A1 Benzoyl amino heterocyclyl compounds as glucokinase (GLK) activators |